• Medientyp: E-Artikel
  • Titel: Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort
  • Beteiligte: Casco, Nicolas; Jorge, Alberto Levi; Palmero, Domingo Juan; Alffenaar, Jan-Willem; Fox, Greg J.; Ezz, Wafaa; Cho, Jin-Gun; Denholm, Justin; Skrahina, Alena; Solodovnikova, Varvara; Arbex, Marcos Abdo; Alves, Tatiana; Rabahi, Marcelo Fouad; Pereira, Giovana Rodrigues; Sales, Roberta; Silva, Denise Rossato; Saffie, Muntasir M.; Salinas, Nadia Escobar; Miranda, Ruth Caamaño; Cisterna, Catalina; Concha, Clorinda; Fernandez, Israel; Villalón, Claudia; Vera, Carolina Guajardo; [...]
  • Erschienen: European Respiratory Society (ERS), 2023
  • Erschienen in: European Respiratory Journal
  • Sprache: Englisch
  • DOI: 10.1183/13993003.00925-2023
  • ISSN: 0903-1936; 1399-3003
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Background</jats:title><jats:p>Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes of patients affected by TB and COVID-19.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We collected data from 174 centres in 31 countries on all patients affected by COVID-19 and TB between 1 March 2020 and 30 September 2022. Patients were followed-up until cure, death or end of cohort time. All patients had TB and COVID-19; for analysis purposes, deaths were attributed to TB, COVID-19 or both. Survival analysis was performed using Cox proportional risk-regression models, and the log-rank test was used to compare survival and mortality attributed to TB, COVID-19 or both.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Overall, 788 patients with COVID-19 and TB (active or sequelae) were recruited from 31 countries, and 10.8% (n=85) died during the observation period. Survival was significantly lower among patients whose death was attributed to TB and COVID-19<jats:italic>versus</jats:italic>those dying because of either TB or COVID-19 alone (p&lt;0.001). Significant adjusted risk factors for TB mortality were higher age (hazard ratio (HR) 1.05, 95% CI 1.03–1.07), HIV infection (HR 2.29, 95% CI 1.02–5.16) and invasive ventilation (HR 4.28, 95% CI 2.34–7.83). For COVID-19 mortality, the adjusted risks were higher age (HR 1.03, 95% CI 1.02–1.04), male sex (HR 2.21, 95% CI 1.24–3.91), oxygen requirement (HR 7.93, 95% CI 3.44–18.26) and invasive ventilation (HR 2.19, 95% CI 1.36–3.53).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In our global cohort, death was the outcome in &gt;10% of patients with TB and COVID-19. A range of demographic and clinical predictors are associated with adverse outcomes.</jats:p></jats:sec>